Tesamorelin

Mechanism

Tesamorelin is a synthetic analog of human GHRH(1-44) with a trans-3-hexenoic acid group attached to the tyrosine at position 1 via the amino terminus. This modification provides resistance to enzymatic degradation by DPP-IV, extending its biological activity. Like native GHRH, tesamorelin activates the GHRH receptor on pituitary somatotrophs to stimulate pulsatile GH release and subsequent hepatic IGF-1 production. Studies have investigated its effects on visceral adipose tissue metabolism, demonstrating modulation of trunk fat distribution, with observations of changes in trunk fat-to-limb fat ratio in research settings.

What the literature has looked at

• Studies have investigated GHRH receptor-mediated effects on visceral adipose tissue metabolism
• Research has examined effects on hepatic lipid content and related biomarkers
• Studies have investigated cognitive signaling effects in aging research models
• Research has assessed effects on cardiovascular biomarkers including triglycerides and CRP

Research context, not a claim about what this compound does. Research Use Only — not for human or animal consumption. 21+.

Cited work

• Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.

  Research investigated GHRH receptor-mediated effects on visceral adipose tissue metabolism over 26 weeks, observing modulation of adipose tissue distribution parameters.

• Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.

  Research examined the relationship between GHRH receptor activation and hepatic lipid metabolism, investigating effects on both visceral adipose tissue and hepatic fat fraction biomarkers.

Properties

type

Peptide (modified GHRH analog)